Table of Contents

1 Study Coverage

• 1.1 Antineoplastic Drugs Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Antineoplastic Drugs Market Size Growth Rate by Product
  • 1.4.2 Chemotherapeutic Agents
  • 1.4.3 Biological/Immunotherapeutic Agents
  • 1.4.4 Personalized Medicine
• 1.5 Market by End User
  • 1.5.1 Global Antineoplastic Drugs Market Size Growth Rate by End User
  • 1.5.2 Hospitals
  • 1.5.3 Clinics
  • 1.5.4 Cancer Rehabilitation Centers
  • 1.5.5 Ambulatory Surgical Centers
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Antineoplastic Drugs Market Size
  • 2.1.1 Global Antineoplastic Drugs Revenue 2014-2025
  • 2.1.2 Global Antineoplastic Drugs Sales 2014-2025
• 2.2 Antineoplastic Drugs Growth Rate by Regions
  • 2.2.1 Global Antineoplastic Drugs Sales by Regions
  • 2.2.2 Global Antineoplastic Drugs Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Antineoplastic Drugs Sales by Manufacturers
  • 3.1.1 Antineoplastic Drugs Sales by Manufacturers
  • 3.1.2 Antineoplastic Drugs Sales Market Share by Manufacturers
  • 3.1.3 Global Antineoplastic Drugs Market Concentration Ratio (CR5 and HHI)
• 3.2 Antineoplastic Drugs Revenue by Manufacturers
  • 3.2.1 Antineoplastic Drugs Revenue by Manufacturers (2014-2019)
  • 3.2.2 Antineoplastic Drugs Revenue Share by Manufacturers (2014-2019)
• 3.3 Antineoplastic Drugs Price by Manufacturers
• 3.4 Antineoplastic Drugs Manufacturing Base Distribution, Product Types
  • 3.4.1 Antineoplastic Drugs Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Antineoplastic Drugs Product Type
  • 3.4.3 Date of International Manufacturers Enter into Antineoplastic Drugs Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Antineoplastic Drugs Sales by Product
• 4.2 Global Antineoplastic Drugs Revenue by Product
• 4.3 Antineoplastic Drugs Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Antineoplastic Drugs Breakdown Data by End User

6 North America

• 6.1 North America Antineoplastic Drugs by Countries
  • 6.1.1 North America Antineoplastic Drugs Sales by Countries
  • 6.1.2 North America Antineoplastic Drugs Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Antineoplastic Drugs by Product
• 6.3 North America Antineoplastic Drugs by End User

7 Europe

• 7.1 Europe Antineoplastic Drugs by Countries
  • 7.1.1 Europe Antineoplastic Drugs Sales by Countries
  • 7.1.2 Europe Antineoplastic Drugs Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Antineoplastic Drugs by Product
• 7.3 Europe Antineoplastic Drugs by End User

8 Asia Pacific

• 8.1 Asia Pacific Antineoplastic Drugs by Countries
  • 8.1.1 Asia Pacific Antineoplastic Drugs Sales by Countries
  • 8.1.2 Asia Pacific Antineoplastic Drugs Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Antineoplastic Drugs by Product
• 8.3 Asia Pacific Antineoplastic Drugs by End User

9 Central & South America

• 9.1 Central & South America Antineoplastic Drugs by Countries
  • 9.1.1 Central & South America Antineoplastic Drugs Sales by Countries
  • 9.1.2 Central & South America Antineoplastic Drugs Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Antineoplastic Drugs by Product
• 9.3 Central & South America Antineoplastic Drugs by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Antineoplastic Drugs by Countries
  • 10.1.1 Middle East and Africa Antineoplastic Drugs Sales by Countries
  • 10.1.2 Middle East and Africa Antineoplastic Drugs Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Antineoplastic Drugs by Product
• 10.3 Middle East and Africa Antineoplastic Drugs by End User

11 Company Profiles

• 11.1 Hoffmann-La Roche
  • 11.1.1 Hoffmann-La Roche Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Hoffmann-La Roche Antineoplastic Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Hoffmann-La Roche Antineoplastic Drugs Products Offered
  • 11.1.5 Hoffmann-La Roche Recent Development
• 11.2 Amgen
  • 11.2.1 Amgen Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Amgen Antineoplastic Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Amgen Antineoplastic Drugs Products Offered
  • 11.2.5 Amgen Recent Development
• 11.3 Bristol-Myers Squibb
  • 11.3.1 Bristol-Myers Squibb Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Bristol-Myers Squibb Antineoplastic Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Bristol-Myers Squibb Antineoplastic Drugs Products Offered
  • 11.3.5 Bristol-Myers Squibb Recent Development
• 11.4 Baxter Healthcare
  • 11.4.1 Baxter Healthcare Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Baxter Healthcare Antineoplastic Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Baxter Healthcare Antineoplastic Drugs Products Offered
  • 11.4.5 Baxter Healthcare Recent Development
• 11.5 Boehringer Ingelheim
  • 11.5.1 Boehringer Ingelheim Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Boehringer Ingelheim Antineoplastic Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Boehringer Ingelheim Antineoplastic Drugs Products Offered
  • 11.5.5 Boehringer Ingelheim Recent Development
• 11.6 Aspen Global
  • 11.6.1 Aspen Global Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Aspen Global Antineoplastic Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Aspen Global Antineoplastic Drugs Products Offered
  • 11.6.5 Aspen Global Recent Development
• 11.7 Bayer AG
  • 11.7.1 Bayer AG Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Bayer AG Antineoplastic Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Bayer AG Antineoplastic Drugs Products Offered
  • 11.7.5 Bayer AG Recent Development
• 11.8 Teva pharmaceutical Industries
  • 11.8.1 Teva pharmaceutical Industries Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Teva pharmaceutical Industries Antineoplastic Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Teva pharmaceutical Industries Antineoplastic Drugs Products Offered
  • 11.8.5 Teva pharmaceutical Industries Recent Development
• 11.9 Johnson & Johnson
  • 11.9.1 Johnson & Johnson Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Johnson & Johnson Antineoplastic Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Johnson & Johnson Antineoplastic Drugs Products Offered
  • 11.9.5 Johnson & Johnson Recent Development
• 11.10 Merc & Co.
  • 11.10.1 Merc & Co. Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 Merc & Co. Antineoplastic Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 Merc & Co. Antineoplastic Drugs Products Offered
  • 11.10.5 Merc & Co. Recent Development
• 11.11 Pfize
• 11.12 Accord Healthcare
• 11.13 Genentech
• 11.14 Lundbeck
• 11.15 AbbVie

12 Future Forecast

• 12.1 Antineoplastic Drugs Market Forecast by Regions
  • 12.1.1 Global Antineoplastic Drugs Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Antineoplastic Drugs Revenue Forecast by Regions 2019-2025
• 12.2 Antineoplastic Drugs Market Forecast by Product
  • 12.2.1 Global Antineoplastic Drugs Sales Forecast by Product 2019-2025
  • 12.2.2 Global Antineoplastic Drugs Revenue Forecast by Product 2019-2025
• 12.3 Antineoplastic Drugs Market Forecast by End User
• 12.4 North America Antineoplastic Drugs Forecast
• 12.5 Europe Antineoplastic Drugs Forecast
• 12.6 Asia Pacific Antineoplastic Drugs Forecast
• 12.7 Central & South America Antineoplastic Drugs Forecast
• 12.8 Middle East and Africa Antineoplastic Drugs Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Antineoplastic Drugs Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

The global Antineoplastic Drugs market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Antineoplastic Drugs market based on company, product type, end user and key regions.

This report studies the global market size of Antineoplastic Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Antineoplastic Drugs in these regions.
This research report categorizes the global Antineoplastic Drugs market by top players/brands, region, type and end user. This report also studies the global Antineoplastic Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Hoffmann-La Roche
Amgen
Bristol-Myers Squibb
Baxter Healthcare
Boehringer Ingelheim
Aspen Global
Bayer AG
Teva pharmaceutical Industries
Johnson & Johnson
Merc & Co.
Pfize
Accord Healthcare
Genentech
Lundbeck
AbbVie

Market size by Product
Chemotherapeutic Agents
Biological/Immunotherapeutic Agents
Personalized Medicine
Market size by End User
Hospitals
Clinics
Cancer Rehabilitation Centers
Ambulatory Surgical Centers

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Antineoplastic Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Antineoplastic Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Antineoplastic Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Antineoplastic Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Antineoplastic Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Antineoplastic Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.